Mechanistic review uncovers coagulation activation by corisin in COVID-19 patients, highlighting the pathological link between microbiome dysbiosis and thrombosis.
Coagulopathy is a major cause of morbidity and mortality in COVID-19 patients. Hypercoagulability in COVID-19 results in deep vein thrombosis, thromboembolic complications, and diffuse intravascular coagulation. Microbiome dysbiosis influences the clinical course of COVID-19. However, the role of dysbiosis in COVID-19-associated coagulopathy is not fully understood.
No takes yet. Share an insight, caveat, or question.
Tsuruga et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: